Compare abrdn Income Credit Strategies Fund (ACP) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
abrdn Income Credit Strategies Fund vs State Street SPDR S&P Biotech ETF — how do they compare? abrdn Income Credit Strategies Fund trades at $5.15 (market cap $641.16M), while State Street SPDR S&P Biotech ETF trades at $159.34. The key difference: abrdn Income Credit Strategies Fund pays a 18.2% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, abrdn Income Credit Strategies Fund nearer its low. Which is the better fit depends on your goals.
| ACP | XBI | |
|---|---|---|
Market Cap | $641.16M | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $5.98 | $164.28 |
52-Week Low | $5.01 | $86.92 |
Dividend Yield | 18.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACP trades at $5.14, up 1.18% today, with a neutral technical signal and bearish moving averages. The stock shows strong profitability with a net income margin of 95.31% and a low P/E of 7.74, though revenue declined to $42.46M in 2025 from $79M in 2024. Recent news highlights dividend declarations and a Seeking Alpha downgrade citing distribution sustainability concerns.
The outlook is mixed: attractive valuation and high dividends offer income appeal, but revenue volatility and high leverage pose risks. Analyst sentiment is cautious due to unsustainable distribution rates and tight credit spreads, requiring careful monitoring of earnings and credit conditions for future performance.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end investment management company. Its primary goal is to generate high current income, with capital appreciation as a secondary objective. The fund mainly invests in debt and loan instruments from issuers across various industries and regions.
Read more on ACP →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
